NCT07369375

Efficacy and Safety of VMX Eye Drops for Dry Eye Disease

Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VMX Eye Drops for the Treatment of Dry Eye Disease (DED)

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 76 (estimated)
• Sponsor: VISUfarma SpA · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This multicenter, randomized, double-blind study evaluates the safety and effectiveness of VMX eye drops in patients with dry eye disease. It aims to improve tear film stability, reduce dry eye symptoms, and enhance patients' quality of life compared to standard treatment.

Conditions

• Dry Eye Disease (DED)

Interventions

Type	Name	Description
DEVICE	VMX Eye Drops	VMX ophthalmic solution; the dosage is one drop in each eye three times a day for 56 days.
DEVICE	placebo eye drops	Sterile ophthalmic solution. The dosage is one drop in each eye three times a day for 56 days.

Timeline

• Start date: 2026-02-02
• Primary completion: 2026-06-01
• Completion: 2026-06-01
• First posted: 2026-01-27
• Last updated: 2026-01-29